Latest News
10-01-18 Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) 09-25-18 Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology 09-04-18 Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) more »Spotlight on Clinical Studies
The Zogenix study entitled "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Audlts with Lennox-Gastaut Syndrome" is being conducted for patients with Lennox-Gastaut syndrome who are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT03355209).
more »Scientific Publications
- Effect of ZX008 on Total Seizures in Dravet Syndrome in a Phase 3 Clinical Trial
- ZX008 in Dravet Syndrome: Effect on Convulsive Seizure Frequency in Subjects Who Failed Treatment with Stiripentol Prior to Study 1, Phase 3 Trial
- ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial